HC Wainwright & Co. Maintains Buy on Deciphera Pharmaceuticals, Raises Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein maintains a 'Buy' rating on Deciphera Pharmaceuticals (NASDAQ:DCPH) and raises the price target from $25 to $30.
October 31, 2023 | 11:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Deciphera Pharmaceuticals' price target has been raised from $25 to $30 by HC Wainwright & Co. The firm maintains a 'Buy' rating on the stock.
The raised price target and maintained 'Buy' rating by HC Wainwright & Co. indicates a positive outlook for Deciphera Pharmaceuticals. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100